Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...

The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care-;announces the publication of ...

ITDD helps effectively manage chronic pain and spasticity in some patients but requires adherence to best practices and a ...

This important study demonstrated that ablation of astrocytes in the lumbar spinal cord not only reduced neuropathic pain but also caused microglia activation. The findings presented add considerable ...

On shorter reports–under five pages–the Table of Content, List of Illustrations, and Executive Summary parts might not be required. Most common is one-inch margins all around. Use your word-processing ...

Boston biotech Ax­o­nis Ther­a­peu­tics has raised a $115 mil­lion Se­ries A to test whether its oral drug AXN-027 can help pa­tients with fo­cal epilep­sy and … ...

More information: Mikael Åkerlund et al, Genetic associations of neuropathic pain and sensory profile in a deeply phenotyped neuropathy cohort, Pain (2024). DOI: 10.1097/j.pain.0000000000003463 ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

Many clients that I see suffer from chronic pain or chronic medical conditions, often in addition to other disorders like depression, anxiety, PTSD, ADHD, and so forth. Also, I have experienced ...

Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev ... Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical ...

More information: Carlos Raul Ramirez Medina et al, Clinical indications associated with new opioid use for pain management in the United Kingdom: using national primary care data, Pain (2024).

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...